Insulin treatment normalizes retinal neuroinflammation but not markers of synapse loss in diabetic rats

Experimental Eye Research

Volumn 125, Issue , 2014, Pages 95-106

  Masser, Dustin R ^a,b,c   VanGuilder Starkey, Heather D ^a,d   Bixler, Georgina V ^a   Dunton, Wendy ^a   Bronson, Sarah K ^a,d   Freeman, Willard M ^a,b,c,d  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c Reynolds Oklahoma Center on Aging   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Diabetes; Insulin; Metabolic memory; Neuroinflammation; Retina; Synapse

Indexed keywords

BIOLOGICAL MARKER; BRANCHED CHAIN AMINO ACID; C PEPTIDE; CELL MARKER; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; CELL COUNT; CELL LOSS; CONTROLLED STUDY; DIABETIC RETINOPATHY; EARLY INTERVENTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN IMPLANT; INSULIN TREATMENT; MALE; METABOLIC DISORDER; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RETINA NERVE CELL; RETINITIS; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYNAPSE; SYSTEMIC THERAPY; THERAPY DELAY; TREATMENT DURATION; WEIGHT GAIN;

DIABETES; INSULIN; METABOLIC MEMORY; NEUROINFLAMMATION; RETINA; SYNAPSE;

AMINO ACIDS, BRANCHED-CHAIN; ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION PROFILING; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN; KETONES; RATS, SPRAGUE-DAWLEY; RETINA; RETINITIS; SYNAPSES;

EID: 84904629279     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2014.06.005     Document Type: Article

References (51)

1. Aiello L.P. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014, 37:17-23. DCCT/EDIC Research Group.
2. Antonetti D.A., Barber A.J., Bronson S.K., Freeman W.M., Gardner T.W., Jefferson L.S., Kester M., Kimball S.R., Krady J.K., LaNoue K.F., Norbury C.C., Quinn P.G., Sandirasegarane L., Simpson I.A., Group J.D.R.C. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006, 55:2401-2411.
3. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. N.Engl. J. Med. 2012, 366:1227-1239.
4. Araszkiewicz A., Zozulinska-Ziolkiewicz D., Meller M., Bernardczyk-Meller J., Pilacinski S., Rogowicz-Frontczak A., Naskret D., Wierusz-Wysocka B. Neurodegeneration of the retina in type 1 diabetic patients. Pol. Arch. Med. Wewnetrznej 2012, 122:464-470.
5. Asnaghi V., Gerhardinger C., Hoehn T., Adeboje A., Lorenzi M. Arole for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003, 52:506-511.
6. Aung M.H., Kim M.K., Olson D.E., Thule P.M., Pardue M.T. Early visual deficits in streptozotocin-induced diabetic long evans rats. Investig. Ophthalmol. Vis. Sci. 2013, 54:1370-1377.
7. Barber A.J., Antonetti D.A., Gardner T.W. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Investig. Ophthalmol. Vis. Sci. 2000, 41:3561-3568.
8. Barber A.J., Antonetti D.A., Kern T.S., Reiter C.E., Soans R.S., Krady J.K., Levison S.W., Gardner T.W., Bronson S.K. The Ins2Akita mouse as a model of early retinal complications in diabetes. Investig. Ophthalmol. Vis. Sci. 2005, 46:2210-2218.
9. Barber A.J., Gardner T.W., Abcouwer S.F. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2011, 52:1156-1163.
10. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J.Clin. Investig. 1998, 102:783-791.
11. Beckett P.R. Spectrophotometric assay for measuring branched-chain amino acids. Methods Enzym. 2000, 324:40-47.
12. Benjamini Y., Drai D., Elmer G., Kafkafi N., Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 2001, 125:279-284.
13. Bixler G.V., Vanguilder H.D., Brucklacher R.M., Kimball S.R., Bronson S.K., Freeman W.M. Chronic insulin treatment of diabetes does not fully normalize alterations in the retinal transcriptome. BMC Med. Genomics 2011, 4:40.
14. Brucklacher R.M., Patel K.M., VanGuilder H.D., Bixler G.V., Barber A.J., Antonetti D.A., Lin C.M., LaNoue K.F., Gardner T.W., Bronson S.K., Freeman W.M. Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med. Genomics 2008, 1:26.
15. Engerman R.L., Kern T.S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36:808-812.
16. Fernandez D.C., Pasquini L.A., Dorfman D., Aldana Marcos H.J., Rosenstein R.E. Early distal axonopathy of the visual pathway in experimental diabetes. Am. J. Pathol. 2012, 180:303-313.
17. Freeman W.M., Bixler G.V., Brucklacher R.M., Lin C.M., Patel K.M., VanGuilder H.D., LaNoue K.F., Kimball S.R., Barber A.J., Antonetti D.A., Gardner T.W., Bronson S.K. Amultistep validation process of biomarkers for preclinical drug development. Pharmacogenomics J. 2010, 10:385-395.
18. Gastinger M.J., Singh R.S., Barber A.J. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Investig. Ophthalmol. Vis. Sci. 2006, 47:3143-3150.
19. Gaucher D., Chiappore J.A., Paques M., Simonutti M., Boitard C., Sahel J.A., Massin P., Picaud S. Microglial changes occur without neural cell death in diabetic retinopathy. Vis. Res. 2007, 47:612-623.
20. Gerhardinger C., Costa M.B., Coulombe M.C., Toth I., Hoehn T., Grosu P. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Investig. Ophthalmol. Vis. Sci. 2005, 46:349-357.
21. Group, T.D.C.a.C.T.R. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the diabetes control and complications Trial. Diabetes Care 2001, 24:1711-1721.
22. Hollander H., Makarov F., Dreher Z., van Driel D., Chan-Ling T.L., Stone J. Structure of the macroglia of the retina: sharing and division of labour between astrocytes and Muller cells. J.Comp. Neurol. 1991, 313:587-603.
23. Ibrahim A.S., El-Remessy A.B., Matragoon S., Zhang W., Patel Y., Khan S., Al-Gayyar M.M., El-Shishtawy M.M., Liou G.I. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes 2011, 60:1122-1133.
24. Intine R.V., Sarras M.P. Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms. Curr. Diabetes Rep. 2012, 12:551-559.
25. Jackson G.R., Barber A.J. Visual dysfunction associated with diabetic retinopathy. Curr. Diabetes Rep. 2010, 10:380-384.
26. Kastelan S., Tomic M., Gverovic Antunica A., Salopek Rabatic J., Ljubic S. Inflammation and pharmacological treatment in diabetic retinopathy. Mediat. Inflamm. 2013, 2013:213130.
27. Kern T.S., Barber A.J. Retinal ganglion cells in diabetes. J.Phys. 2008, 586:4401-4408.
28. Kezic J.M., Chen X., Rakoczy E.P., McMenamin P.G. The effects of age and Cx3cr1 deficiency on retinal microglia in the Ins2(Akita) diabetic mouse. Investig. Ophthalmol. Vis. Sci. 2013, 54:854-863.
29. Kohzaki K., Vingrys A.J., Bui B.V. Early inner retinal dysfunction in streptozotocin-induced diabetic rats. Investig. Ophthalmol. Vis. Sci. 2008, 49:3595-3604.
30. Lai A.K., Lo A.C. Animal models of diabetic retinopathy: summary and comparison. J.Diabetes Res. 2013, 2013:106594.
31. Li Q., Zemel E., Miller B., Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp. Eye Res. 2002, 74:615-625.
32. Lieth E., Barber A.J., Xu B., Dice C., Ratz M.J., Tanase D., Strother J.M. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998, 47:815-820.
33. Ly A., Yee P., Vessey K.A., Phipps J.A., Jobling A.I., Fletcher E.L. Early inner retinal astrocyte dysfunction during diabetes and development of hypoxia, retinal stress, and neuronal functional loss. Investig. Ophthalmol. Vis. Sci. 2011, 52:9316-9326.
34. Masliah E., Terry R.D., DeTeresa R.M., Hansen L.A. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett. 1989, 103:234-239.
35. Pietropaolo M., Barinas-Mitchell E., Kuller L.H. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity?. Diabetes 2007, 56:1189-1197.
36. Pirola L., Balcerczyk A., Okabe J., El-Osta A. Epigenetic phenomena linked to diabetic complications. Nature reviews. Endocrinology 2010, 6:665-675.
37. Rosenfalck A.M., Almdal T., Hilsted J., Madsbad S. Body composition in adults with Type 1 diabetes at onset and during the first year of insulin therapy. Diabet. Med. 2002, 19:417-423.
38. Rungger-Brandle E., Dosso A.A., Leuenberger P.M. Glial reactivity, an early feature of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2000, 41:1971-1980.
39. Stroemer R.P., Kent T.A., Hulsebosch C.E. Increase in synaptophysin immunoreactivity following cortical infarction. Neurosci. Lett. 1992, 147:21-24.
40. Tang J., Kern T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30:343-358.
41. Tsai G.Y., Cui J.Z., Syed H., Xia Z., Ozerdem U., McNeill J.H., Matsubara J.A. Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina and plasma of diabetic rats. Clin. Exper. Ophthalmol. 2009, 37:223-231.
42. van Dijk H.W., Verbraak F.D., Stehouwer M., Kok P.H., Garvin M.K., Sonka M., DeVries J.H., Schlingemann R.O., Abramoff M.D. Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy. Vis. Res. 2011, 51:224-228.
43. VanGuilder H.D., Bixler G.V., Kutzler L., Brucklacher R.M., Bronson S.K., Kimball S.R., Freeman W.M. Multi-modal proteomic analysis of retinal protein expression alterations in a rat model of diabetic retinopathy. PloS One 2011, 6:e16271.
44. VanGuilder H.D., Brucklacher R.M., Patel K., Ellis R.W., Freeman W.M., Barber A.J. Diabetes downregulates presynaptic proteins and reduces basal synapsin I phosphorylation in rat retina. Eur. J. Neurosci. 2008, 28:1-11.
45. Villeneuve L.M., Reddy M.A., Natarajan R. Epigenetics: deciphering its role in diabetes and its chronic complications. Clin. Exper. Pharm. Phys. 2011, 38:451-459.
46. Wang H., Ni Y.F., Li H.Z., Yang S., Feng B. Effects of insulin monotherapy on body weight, composition, and fat distribution in newly diagnosed patients with Type 2 diabetes mellitus. J.Diabetes 2013, 5:146-148.
47. Yang L.P., Sun H.L., Wu L.M., Guo X.J., Dou H.L., Tso M.O., Zhao L., Li S.M. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2009, 50:2319-2327.
48. Yang Y., Mao D., Chen X., Zhao L., Tian Q., Liu C., Zhou B.L. Decrease in retinal neuronal cells in streptozotocin-induced diabetic mice. Mol. Vis. 2012, 18:1411-1420.
49. Zeng H.Y., Green W.R., Tso M.O. Microglial activation in human diabetic retinopathy. Arch. Ophthalmol. 2008, 126:227-232.
50. Zhang L., Chen B., Tang L. Metabolic memory: mechanisms and implications for diabetic retinopathy. Diabetes Res. Clin. Pract. 2012, 96:286-293.
51. Zorena K., Raczynska D., Raczynska K. Biomarkers in diabetic retinopathy and the therapeutic implications. Mediat. Inflamm. 2013, 2013:193604.